Table 2.
The clinical samples analysis data for determination of doxorubicin using ds-DNA/SWCNTs/GCE as a new biosensor (n = 4).
Sample | Doxorubicin Added (µM) | Doxorubicin Expected (µM) |
Doxorubicin Founded (µM) | Recovery% (Doxorubicin Founded/Doxorubicin Expected) * 100 |
---|---|---|---|---|
Injection | - | 1.00 | 1.03 ± 0.05 | 103 |
- | 9.00 | 10.00 | 9.72 ± 0.53 | 97.2 |
dextrose saline | - | - | <Limit of detection | - |
- | 10.00 | 10.00 | 9.82 ± 0.53 | 98.2 |
- | 15.00 | 15.00 | 15.74 ± 0.86 | 104.9 |